Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Antacids · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Gleevec plus antacids | EXPERIMENTAL | Gleevec® will be administered at a dose of 400 mg, and the antacid (Maximum Strength Maalox®Max® Antacid/Anti-gas) at a dose level of 20 mL (equivalent to 1600 mg aluminum hydroxide and 1600 mg magnesium hydroxide). Half of the subjects will receive Gleevec® and antacid on day 15 and Gleevec® alone on day 1. |
| Imatimib Mesylate (Gleevec®) | EXPERIMENTAL | Gleevec® will be administered at a dose of 400 mg. Half of the subjects will receive Gleevec® and antacid on day 15 and Gleevec® alone on day 1. The other half will be treated in reverse order, i.e., they will receive the combination of Gleevec® and antacid on day 1, and Gleevec® alone on day 15. The antacids will be administered 15 minutes before the Gleevec® dose. |
| Name | Type | Description |
|---|---|---|
| Antacids (Mg-Al-based) | DRUG | the antacid (Maximum Strength Maalox®Max® Antacid/Anti-gas) at a dose level of 20 mL (equivalent to 1600 mg aluminum hydroxide and 1600 mg magnesium hydroxide). |
| Imatimib Mesylate (Gleevec®) | DRUG | Gleevec® will be administered at a dose of 400 mg. Half of the subjects will receive Gleevec® and antacid on day 15 and Gleevec® alone on day 1. The other half will be treated in reverse order, i.e., they will receive the combination of Gleevec® and antacid on day 1, and Gleevec® alone on day 15. The antacids will be administered 15 minutes before the Gleevec® dose. |
Inclusion Criteria: * Healthy men or women 18 years of age or older. Healthy subjects are defined as individuals who are free from clinically significant illness or disease (such as coronary arterial disease, chronic heart failure, bleeding disorder, hypertension, chronic renal failure etc.) as det...
Antacids is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development, with one completed trial evaluating its effects. The drug is being developed by Novartis AG, which trades on the NYSE under the ticker NVS.
Antacids is being developed by Novartis AG, a pharmaceutical company listed on the NYSE under the ticker NVS. The drug is currently in Phase 1 clinical development, with one completed trial in healthy volunteers.
Antacids is in Phase 1 clinical development. It has one completed trial, NCT00446316, which enrolled 12 healthy volunteers in the United States. The drug is investigational and has not been approved by the FDA.
Antacids has one completed clinical trial, NCT00446316, titled "Effect of Antacids on Gleevec® in Healthy Volunteers." This Phase 1 study enrolled 12 healthy volunteers in the United States and was a controlled, randomized trial.
No, Antacids is not the same as Gleevec. The completed clinical trial NCT00446316 studied the effect of Antacids on Gleevec in healthy volunteers, indicating they are separate drugs. Antacids is an investigational small molecule developed by Novartis AG.